Slide 1: First of a New Class of Antibiotics (pol IIIC Inhibitors)
First of a New Class of Antibiotics (pol IIIC Inhibitors) Targeting CDC/FDA/WHO Priority Pathogens Preparing for the Next Pandemic: Antimicrobial Resistance in Gram-positive Bacterial Infections Presenter: Acurx Medical Director Michael H. Silverman, MD, FACP* Principal Investigator for Microbiome A
Slide 2: Disclosure: Forward-Looking Statements
Disclosure Acurx Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, development plans, regulatory activities, anticipated milestones, product candidate benefits, competitiv
Slide 3: AMR: Global Challenge / Acurx: Company Mission
AMR: GLOBAL CHALLENGE We must prepare our public health systems to fight multiple threats, simultaneously. Now is the time to address our current antimicrobial-resistant threats, while simultaneously preparing for unknown emerging threats in the future.* Unmet Medical Need: CDC/FDA classification:
Slide 4: Acurx Technology and Pipeline
Acurx Technology and Pipeline DNA Polymerase IIIC Inhibition: Innovation criteria1: New chemical class New target New MOA No cross-resistance Gram-Positive Selective Spectrum (GPSS™) antibiotics target all low G + C bacterial pathogens (including C. difficile, MRSA, VRE, DRSP) – FDA QIDP/F
Slide 5: Systemic GPSS Antibiotic: Program Highlights
Systemic GPSS™ Antibiotic: Program Highlights Systemic Pol IIIC Inhibitor Program: Systemic treatment of Staphylococcus, Streptococcus and Enterococcal infections, including MRSA, VRE, and other resistant G+ bacterial infections; WHO/CDC Priority Pathogen Lists1 Novel bactericidal mechanism of ac
Slide 6: Systemic GPSS Antibiotic: Program Status
Systemic GPSS Antibiotic: Program Status ™ Hit-to-Lead testing of >500 novel compounds has resulted in significant advances: In vitro & in vivo safety Oral and IV efficacy in mouse infection models including in neutropenic mice (MRSA systemic & thigh, VRE thigh, and PRSP lung) Early 3D Image Map
Slide 7: Ibezapolstat: Investigating C. difficile Efficacy and Anti-recurrence Properties
Ibezapolstat: ACX-362E Investigating C. difficile Efficacy and Highlights Disclosures Anti-recurrence Properties Clinical development program included a new method to assess for anti-recurrence properties Phase I study: Healthy volunteers High Stool Concentrations Microbiome changes Preservation of
Slide 8: Ibezapolstat: Anti-virulence, Microbiome and MDRO properties
Ibezapolstat: Anti-virulence, Microbiome and MDRO properties REDUCED FLAGELLA EFFECTIVE AGAINST MDRO REDUCED TOXIN EFFECTIVE C. difficile MOVEMENT1 in concert STRAINS1: C. difficile strains PRODUCTION2 KILLING IN BIOFILMS3 with reduced expression of with reduced susceptibility primary genes used to
Slide 9: Promising Signals for Ibezapolstat
Promising Signals for Ibezapolstat Factors that provide confidence in successful outcomes of future clinical trials: Nonclinical Bactericidal potency vs C. difficile Effective against MDR strains Does not trigger sporulation or toxin release Reduced flagellar movement Active in biofilms
Slide 10: Ibezapolstat: Killing the Bug but Sparing the Microbiome
Ibezapolstat: Killing the Bug but Sparing the Microbiome Evaluation of potential anti-recurrence properties earlier in clinical trials could become the new standard for anti-C. difficile drug development Knowledge of novel MOA (DNA inhibitor) led to testable hypotheses of anti-virulence properti